Clinical Trial: Study on the efficacy and safety of Orelabrutinib Combined with Rituximab in the Treatment of Ralapaed and refractory warm Autoimmune Hemolytic Anemia (China)

China, Sept. 3 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Study on the efficacy and safety of Orelabrutinib Combined with Rituximab in the Treatment of Ralapaed and refractory warm Autoimmune Hemolytic Anemia'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131481

Registration Time: 2026/09/02

Type: Interventional study

Primary Sponsor: The First Affiliated Hospital of Zhejiang University School of Medicine

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=334441

Published by HT Digital Content Services with permission from Health Daily Digest....